Abstract
The HER2/neu (HER2) gene is a member of a family of genes which has been implicated in cancer. These four genes, HER1/EGFR, HER2, HER3 and HER4 encode for transmembrane proteins that are involved in the regulation of cell proliferation, differentiation and survival. Amplification of HER2 occurs in 20%-25% of breast cancers and is associated with an aggressive tumor phenotype and poor prognosis. Results from five randomized, phase III clinical trials have recently demonstrated that trastuzumab (Herceptin®) significantly improves disease free survival and overall survival when used in conjunction with chemotherapy for early stage HER2- positive breast cancer. Despite adjuvant trastuzumab, approximately 15% of patients with early stage disease recur, and those with metastatic disease eventually become resistant to therapy. Novel treatment approaches are needed for patients who have either intrinsic or acquired resistance to trastuzumab. This article reviews the role of trastuzumab in managing early and advanced stage HER2-positive disease, the role of lapatinib (Tykerb®) in trastuzumab resistant disease, and the novel agents in development targeting mechanisms of trastuzumab resistance.
Keywords: chemotherapy, Trastuzumab Trials, docetaxel, Disease Free Survival, Cardiotoxicity, Lapatinib
Reviews on Recent Clinical Trials
Title: Targeting the Human Epidermal Growth Factor Receptor 2 (HER2) in the Treatment of Breast Cancer: Recent Advances and Future Directions
Volume: 2 Issue: 2
Author(s): Rita Nanda
Affiliation:
Keywords: chemotherapy, Trastuzumab Trials, docetaxel, Disease Free Survival, Cardiotoxicity, Lapatinib
Abstract: The HER2/neu (HER2) gene is a member of a family of genes which has been implicated in cancer. These four genes, HER1/EGFR, HER2, HER3 and HER4 encode for transmembrane proteins that are involved in the regulation of cell proliferation, differentiation and survival. Amplification of HER2 occurs in 20%-25% of breast cancers and is associated with an aggressive tumor phenotype and poor prognosis. Results from five randomized, phase III clinical trials have recently demonstrated that trastuzumab (Herceptin®) significantly improves disease free survival and overall survival when used in conjunction with chemotherapy for early stage HER2- positive breast cancer. Despite adjuvant trastuzumab, approximately 15% of patients with early stage disease recur, and those with metastatic disease eventually become resistant to therapy. Novel treatment approaches are needed for patients who have either intrinsic or acquired resistance to trastuzumab. This article reviews the role of trastuzumab in managing early and advanced stage HER2-positive disease, the role of lapatinib (Tykerb®) in trastuzumab resistant disease, and the novel agents in development targeting mechanisms of trastuzumab resistance.
Export Options
About this article
Cite this article as:
Nanda Rita, Targeting the Human Epidermal Growth Factor Receptor 2 (HER2) in the Treatment of Breast Cancer: Recent Advances and Future Directions, Reviews on Recent Clinical Trials 2007; 2 (2) . https://dx.doi.org/10.2174/157488707780599375
DOI https://dx.doi.org/10.2174/157488707780599375 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radiation Protection of the Child from Diagnostic Imaging
Current Pediatric Reviews Vascular Targeting: A New Antitumor Activity
Drug Design Reviews - Online (Discontinued) CD147 Interacts with NDUFS6 in Regulating Mitochondrial Complex I Activity and the Mitochondrial Apoptotic Pathway in Human Malignant Melanoma Cells
Current Molecular Medicine Diagnosis and Management of Lynch Syndrome
Recent Patents on Regenerative Medicine A Novel Triazole Derivative Drug Presenting In Vitro and In Vivo Anticancer Properties
Current Topics in Medicinal Chemistry Important Anti-Cancer Applications of Protein Based Nanoparticles
Current Proteomics Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy
Current Cancer Drug Targets Role of Cytokines in Regulating Feeding Behaviour
Current Drug Targets Relative In Vitro Potentials of Parthenolide to Induce Apoptosis and Cell Cycle Arrest in Skin Cancer Cells
Current Drug Discovery Technologies ATP-Binding Cassette Efflux Transporters in Human Placenta
Current Pharmaceutical Biotechnology Genetic Databases and their Potential in Pharmacogenomics
Current Pharmaceutical Design Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System
Current Pharmaceutical Design Antiangiogenic Drugs and Tyrosine Kinases
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Reviews on Recent Clinical Trials Wnt/β-catenin Antagonists: Exploring New Avenues to Trigger Old Drugs in Alleviating Glioblastoma Multiforme
Current Molecular Pharmacology Targeting CD4 to Disrupt Signaling Through Membrane Rafts: Towards a Raft-Based Therapeutics
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Interleukin-6 Trans-Signaling and Colonic Cancer Associated with Inflammatory Bowel Disease
Current Pharmaceutical Design Arginine Deprivation as a Targeted Therapy for Cancer
Current Pharmaceutical Design An Update on Developments in Female Hormonal Contraception
Current Women`s Health Reviews Insight into p95HER2 in Breast Cancer: Molecular Mechanisms and Targeted Therapies
Recent Patents on DNA & Gene Sequences